Schedule a Meeting
Download Brochure
Table of Content
April 2025
.webp)
Principal Consultant
Reviewed By
The global bioprocess containers market size is calculated at US$ 3.12 in 2024, grew to US$ 3.93 billion in 2025, and is projected to reach around US$ 31.91 billion by 2034. The market is expanding at a CAGR of 26.07% between 2025 and 2034.
Flexible fluid-handling devices called bioprocessing containers are made for a range of uses in the biopharmaceutical and life sciences industries. Generally, bags of fluids, including buffers, upstreaming media, and biohazardous waste, are stored and transported in bioprocess containers. Biocontainers are used on a daily basis in the pharmaceutical and scientific research sectors for a variety of purposes that help improve workflow efficiency and operational safety. The most popular containers available are single-use assemblies that do not require post-cleaning. A variety of fittings, connections, filters, and tubing are among the many special parts that these foldable films and poly constructions have to suit a variety of applications.
| Metric | Details |
| Market Size in 2024 | USD 3.12 Billion |
| Projected Market Size in 2034 | USD 31.91 Billion |
| CAGR (2025 - 2034) | 26.07% |
| Leading Region | North America |
| Market Segmentation | By Type, By, Application, By End-use and By Region |
| Top Key Players |
Sartorius AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Danaher Corporation (U.S.), Saint-Gobain (France), Meissner Filtration Products, Inc. (U.S.), Single Use Support (U.S.), Entegris (U.S.), CellBios (India) and Lonza (Switzerland) |
Artificial intelligence opens up new company growth opportunities in the bioprocess container manufacturing industry. By optimizing setup and enhancing product quality evaluation, AI significantly enhances every stage of manufacturing. Bioprocess container activities are continually monitored by technology to verify key indications that are more accurate than human methods at predicting problems.
Focus on cost-effectiveness and single-use containers
Due to reasons such as removing the requirement for sterilization, increasing operating efficiency, and shortening the manufacture time for many pharmaceuticals, the market is growing rapidly due to the increased need for single-use technologies, particularly in biomanufacturing. Additionally, a decrease in production costs is anticipated to boost market expansion. Additionally, single-use bioprocess containers' affordability, sustainability, and lower risk of cross-contamination all support the market's expansion. Nonetheless, the high price of instruments may serve as a barrier to market expansion. Additionally, the introduction of new medications into the market presents a significant growth opportunity for this industry.
High cost of the bioprocess container
One significant barrier to the widespread use of bioprocess containers (BPCs) is the expense of purchasing them in their early phases. Because medical-grade plastic materials used in production must pass strict sterility and quality certification before being made available on the market, BPCs have higher manufacturing costs. These production containers ultimate cost is raised by manufacturing processes and quality checks that demonstrate industry conformance. The initial cost needs of BPCs may provide challenges for small-scale manufacturers and businesses operating in markets that demand price-sensitive output.
Rising demand for biopharmaceuticals
The market for bioprocess containers is mostly driven by the growing need for biopharmaceuticals, especially as the aging population becomes more susceptible to chronic illnesses, including diabetes, cancer, and autoimmune disorders. The demand for sophisticated biologic treatments, such as monoclonal antibodies, vaccines, and cell therapies, is growing as the number of people over 60 continues to rise globally, with notable increases in North America, Europe, and portions of Asia. In order to fulfill the increasing demand, bioprocess containers are vital to the manufacturing, storage, and shipping of these biopharmaceutical goods. The market for bioprocess containers is growing as a result of the increase in biopharmaceutical manufacturing.
By type, the 2D containers segment led the bioprocess containers market in 2024. Single-use 2D bioprocessing containers are made for the biotech, bioprocess, and biopharmaceutical industries to manage media, buffer, harvest, downstream intermediates, and medicinal substances and products efficiently. These containers provide a sterile environment for sensitive biological goods, which helps to preserve product integrity and safety throughout the manufacturing process. They are frequently used in bioprocessing for media storage, buffer solutions, and intermediate product storage. They are a stalwart in the market for bioprocess container solutions because of their flat, flexible shape, which makes handling and storage easier.
By type, the 3D containers segment is estimated to grow at the fastest CAGR in the bioprocess containers market during the forecast period. 3D bioprocess containers, also known as BPCs, are flexible, single-use container solutions that are often employed in the biopharmaceutical sector for crucial liquid handling applications. Alternatives to traditional stainless-steel systems that are more affordable include BPC systems. They use a cutting-edge design methodology that is widely regarded for its adaptability and usefulness. BPC components may easily be included in a range of high-performance systems at every stage of the biologics production process. Because Thermo Fisher Scientific has the biggest inventory of components and libraries in the business, we can combine sensors, tubing, and connections to create a unique.
By application, the upstream process segment held the major share of the bioprocess containers market in 2024. The initial step in the bioprocessing pipeline, upstream processing, is crucial to a number of sectors, such as the production of food, biofuels, and biopharmaceuticals. Laboratory personnel can easily transport fluid media between research centers and store them effectively in cleanrooms as needed, thanks to bioprocess containers. The upstreaming process may be made more effective by having media bags organized within a container so that employees can quickly and easily reach the liquids they need.
By application, the production process segment is estimated to be the fastest-growing in the bioprocess containers market during the predicted time frame. Many of the medications used today are the result of bioprocesses involving animal, yeast, and microbial cell lines. These include tiny compounds like antibiotics, as well as gene therapies and so-called biopharmaceutical (recombinant) proteins. Controlling a bioprocess is essential for optimizing product production, and it is crucial to precisely measure the concentration of the fermentation product, or determinand.
By end-use, the pharmaceutical companies segment held the largest share of the bioprocess containers market in 2024. Drugs with developments in biomedical research opening the door to novel pharmaceutical products, bioprocessing has become a very important area of study. Bioprocessing has made it possible to scale up treatments quickly in the past ten years alone, guaranteeing patients throughout the world a consistent supply of vital biologics. Additionally, it captures the inventive spirit of the pharmaceutical sector, pushing the envelope to better diagnose, treat, and even prevent illnesses.
By end-use, the biotechnology companies segment is estimated to grow at the fastest rate in the bioprocess containers market during 2025-2034. Industrial biotechnology, often known as white biotechnology, uses biological systems and organisms to create processes and products that are beneficial to industry. This topic includes the development of sustainable methods for the creation of chemicals, materials, and energy through the utilization of microbial, plant, and animal cells, as well as enzymes and other biological components. Due to the demand for more effective and sustainable production techniques, industrial biotechnology has developed over the last few decades from a specialized field to an essential part of contemporary industry.
North America dominated the bioprocess containers market share by 41% in 2024. Leading biopharmaceutical companies in the United States territory use BPCs as essential components in their biologic production operations because it has a well-established network of pharmaceutical and biotechnology companies that work with government-backed healthcare research initiatives. Bioprocess containers that offer adaptable, scalable, and effective production capabilities are necessary to meet the expanding market demand for biologics. The region's cutting-edge production facilities and comprehensive framework for carrying out research and development operations are the main reasons for its market supremacy. Regulations that encourage technical innovation and the use of new technologies help the North American market.
With between 30 and 40 percent of the global market, the United States leads the world in per capita prescription drug spending. The early stages of drug discovery are heavily influenced by biotech firms and pharmaceutical manufacturers in addition to NIH research. After that, these businesses work with the Food and Drug Administration (FDA) to develop and approve the medication before releasing it onto the American market. Pharmaceuticals were the seventh-largest exported product in the US (out of 97) in 2024, with $94.4 billion in exports. Pharmaceuticals were the fifth-largest imported product (out of 97) in the US in 2024, with $212 billion in imports.
By advancing medical research and bringing new medications and vaccines to market, the pharmaceutical industry actively supports the health and well-being of Canadians while also making a direct economic contribution to the country. The pharmaceutical industry's economic impact may be measured in a number of ways, including R&D investment, employment and job creation, government tax income, and international commerce.
Asia Pacific is estimated to host the fastest-growing bioprocess containers market during the forecast period. Government funding for biopharmaceutical research, increased disposable money, and healthcare awareness are some of the factors driving the Asia-Pacific biopharmaceutical industry. In the area, the number of CROs and CMOs that need single-use bioprocess containers for their production processes is also rising quickly. China and India provide a plethora of opportunities for outsourcing manufacturing operations due to their low production prices, skilled labor costs, and government incentives to encourage foreign companies in the pharmaceutical industry. Important market participants also focus on expanding their footprint in Asia-Pacific by forming alliances, purchasing local businesses, and entering into contract manufacturing arrangements with them.
As the greatest developing nation and the second-largest economy in the world, China's market and economy have taken center stage in the Asia-Pacific area. China's national economy depends heavily on the pharmaceutical sector, which has a significant demand, need, and capacity for innovation. High rates of growth are still being seen by the sector. The expansion of China's pharmaceutical business is gaining steam due to the country's growing focus on the pharmaceutical sector and its gradually improving healthcare regulations. The overall Chinese pharmaceutical market has exhibited a steady and encouraging trend as the industry's market structure continues to improve, and its present benefits and potential are drawing more and more foreign businesses to conduct business in China.
The nation now accounts for around 10% of global output by volume and 1.5% by value, ranking third in terms of production volume and fourteenth in terms of value. It is ranked fourth in the world for generic manufacture and seventeenth for the value of bulk active ingredients and dosage forms exported. More than 200 nations worldwide, including the highly controlled markets of the US, West Europe, Japan, and Australia, are the final destination for Indian exports. It has made great strides in the development of infrastructure, technology-based innovation, and a variety of goods. It has demonstrated its core values and resolve to thrive in the ever-evolving environment.
Europe is expected to grow significantly in the bioprocess containers market during the forecast period. In order to maintain compliance and operational efficiency, the region's strict regulatory criteria for medication research and manufacturing procedures have sped up the adoption of single-use bioprocessing systems. The need for fluid transfer systems and bioprocess containers is further fueled by European efforts that emphasize economical and sustainable production methods. In Europe, partnerships between academic institutions and business leaders also promote innovation and the creation of cutting-edge bioprocessing technology.
The government intends to make the bio sciences a major component of its next industry strategy, as it has determined that it is one of the industries in the UK with the greatest development potential. The government has given the NHS more money than was anticipated during the 2023 VPAG discussions. More NHS activity as a result of increased financing has eventually increased demand for medications, which the industry must pay for.
In April 2024, Darren Verlenden, Head of Process Solutions for Merck's Life Science business area, stated, "We are dedicated to offering our customers solutions that address their challenges in single-use manufacturing." Our creative use of woven nylon guarantees the film's durability while offering the flexibility, ease of handling, and container conformance required for single-use processing.
By Type
By Application
By End-use
By Region
April 2025
April 2025
April 2025
April 2025